Loading
Bladder and Urothelial Cancer Treatments · Journal article
Iju Case Reports · August 18, 2026
Raises a question worth testing. It does not answer one.
This case report describes an individual patient with metastatic bladder squamous cell carcinoma who achieved complete response and prolonged survival (41 months from diagnosis, 30 months post-metastasis) following pembrolizumab monotherapy, despite biomarkers typically associated with poor checkpoint inhibitor response (PD-L1 negativity, microsatellite stability, low tumor mutational burden). The observation raises hypothesis about pembrolizumab efficacy in this rare histology but provides no evidence generalizable beyond this single patient.
Single-case report. One 49-year-old male with pure bladder squamous cell carcinoma arising from a diverticulum with pelvic lymph node involvement.. Intervention: Pembrolizumab monotherapy; isolated hilar lymph node progression managed with radiotherapy.. n = 1.
49-year-old male with pure bladder squamous cell carcinoma from diverticulum with pelvic lymph node involvement Pulmonary metastases developed 6 months post-cystectomy; platinum rechallenge led to rapid progression with pleural dissemination Pembrolizumab produced complete response despite PD-L1 negativity, microsatellite stability, and low tumor mutational burden
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case does not establish evidence for clinical practice. It documents an unexpected response in a single patient with rare histology and adverse biomarkers, which may warrant hypothesis generation for future prospective study but should not guide treatment decisions in the absence of controlled data.
A single case report of unexpected response to checkpoint inhibition in a rare cancer subtype raises a mechanistic question but provides no comparative evidence, control group, or generalizable data.
As stated by the source record.
Quoted from the source exactly as published.
This case does not establish evidence for clinical practice. It documents an unexpected response in a single patient with rare histology and adverse biomarkers, which may warrant hypothesis generation for future prospective study but should not guide treatment decisions in the absence of controlled data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Introduction Squamous cell carcinoma is a rare bladder cancer subtype with poor prognosis in advanced stages. Currently, there is no established systemic therapy, including immune checkpoint inhibitors, for this subtype. Case Presentation A 49‐year‐old man with pure bladder squamous cell carcinoma arising from a diverticulum with pelvic lymph node involvement underwent neoadjuvant gemcitabine plus cisplatin followed by robot‐assisted radical cystectomy. Six months later, pulmonary metastases developed, and platinum rechallenge led to rapid progression with pleural dissemination. Pembrolizumab produced a complete response despite programmed cell death ligand‐1 negativity, microsatellite stability, and low tumor mutational burden. Isolated hilar lymph node progression during treatment was managed with radiotherapy, achieving temporary local control. The patient survived 41 months from diagnosis and 30 months after metastasis. Conclusion Despite early and aggressive metastatic recurrence after robot‐assisted radical cystectomy, the patient showed a remarkable and durable response to pembrolizumab.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.